Phio Pharmaceuticals PHIO
NASDAQ PHIO
$1.03 +0.00 (+0.00%)
At close: Sep 9, 2026 · 4:00 PM EDT

Phio Pharmaceuticals (PHIO) Net Margin (2012 - 2019)

Phio Pharmaceuticals' (PHIO) quarterly Net Margin came in at 10219.05% in Q1 2019, down 48427.0% on a YoY basis from N/an in Q1 2018, and down 290.14% quarter-over-quarter from 2619.3% in Q3 2018.

Analysis

Phio Pharmaceuticals (PHIO) Net Margin (2012 - 2019) Analysis & Trends

Phio Pharmaceuticals (PHIO) has reported Net Margin for 8 consecutive years, with 10219.05% the latest figure, recorded in Q1 2019.

  • For the quarter ending Q1 2019, Net Margin fell 48427.0% year-over-year to 10219.05%; the trailing twelve-month figure through Dec 2019 stood at 42795.24% (down 3746190.0% YoY), and the FY2019 full-year result was 42419.05%, down 3708571.0% from the prior year.
  • Net Margin retreated to 10219.05% in Q1 2019 per PHIO's latest filing, from 2619.3% in the prior quarter.
  • Across five years, Net Margin topped out at 2619.3% in Q3 2018 and bottomed at 24577.78% in Q2 2016.
  • Historically, Net Margin has averaged 11911.38% across 5 years, with a median of 9976.92% in 2018.
  • The sharpest annual moves came in 2015 and 2016: Net Margin surged 472170 bps in 2015, then slumped 1310412 bps in 2016.
  • Over 5 years, Net Margin stood at 9205.88% in 2015, then slumped by 167 bps to 24577.78% in 2016, then jumped by 46 bps to 13346.67% in 2017, then soared by 80 bps to 2619.3% in 2018, then slumped by 290 bps to 10219.05% in 2019.
  • According to Business Quant data, Net Margin over the past three periods registered 10219.05%, 2619.3%, and 3277.59% for Q1 2019, Q3 2018, and Q2 2018 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 23.62%
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -134.51%
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 32.99%
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 30.23%
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 31.16%
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -539.31%
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 12.74%
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 3.56%
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -20,152.98%
10 Phio Pharmaceuticals 12.08 Mn 12.08 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 -10,219.05%
Sep 30, 2018 -2,619.30%
Jun 30, 2018 -3,277.59%
Mar 31, 2018 -9,734.78%
Dec 31, 2017 -13,346.67%
Jun 30, 2016 -24,577.78%
Mar 31, 2016 -22,310.00%
Mar 31, 2015 -9,205.88%
Dec 31, 2014 -19,757.14%
Sep 30, 2014 -18,162.50%
Jun 30, 2014 -26,825.00%
Mar 31, 2014 -13,927.59%
Dec 31, 2013 -12,844.83%
Sep 30, 2013 -3,810.87%
Jun 30, 2013 -1,937.78%
Mar 31, 2013 -33,856.60%
Dec 31, 2012 -6,575.00%
Sep 30, 2012 -5,124.56%